Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says

• Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly

  It is made possible through a first-of-a-kind integration with Eli Lilly's direct-to-consumer website, and aims to streamline access to the popular treatment.
  
  CNBC - 10h

• Some health experts warn against microdosing weight loss drugs

  The demand for weight loss drugs, like Ozempic and Wegovy, has skyrocketed in the past few years despite the high cost and unpleasant side effects for some people. The New York Times reports some ...
  
  CBS News - 1d

• The weight-loss drug boom has become one of the internet's biggest scams

  As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according to cybersecurity experts.
  
  CNBC - 3d
• 

  Weight-loss drug Mounjaro 'changed my life,' says mother-of-two

  People struggling with their weight welcome the NHS rollout of Mounjaro but worry about delays.
  
  BBC News - 6d
• 

  Millions will have to wait up to 12 years for NHS weight-loss drug

  Fears that giving 3.4 million people immediate access to new weight-loss drug could overwhelm NHS.
  
  BBC News - 6d
• 

  Zepbound brings more weight loss than Wegovy: Drugmaker

  Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from their ...
  
  The Hill - Dec. 4

• Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy

  Zepbound helped patients lose more weight than a major rival in a head-to-head trial.
  
  MarketWatch - Dec. 4
• 

  A rival weight loss drug to Wegovy helped people shed more pounds, study shows

  People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical trial, Lilly said in a release Wednesday.
  
  NBC News - Dec. 4

• Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

  Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
  
  CNBC - Dec. 4

More from CNBC

• Alphabet and Tesla reach fresh records, joining Amazon and Meta and pushing Nasdaq past 20,000

  CNBC - 2h

• Murder suspect Luigi Mangione's notebook called 'wack' of CEO 'targeted, precise'

  CNBC - 1h

• If Trump wants to kill inflation, the first thing he needs to do is get more homes built

  CNBC - 3h

• ETFs cross $1 trillion of inflows in 2024, extending record year

  CNBC - 3h

• Budget deficit swells in November, pushing fiscal 2025 shortfall 64% higher than a year ago

  CNBC - 3h